Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia <p>Leukemia, Published online: 24 February 2026; <a href="https://www.nature.com/articles/s41375-026-02867-9">doi:10.1038/s41375-026-02867-9</a></p>Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia Leukemia Journal February 26, 2026 Original source
Risk stratification of patients with <i>TP53</i>-mutated myeloproliferative neoplasms <p>Leukemia, Published online: 24 February 2026; <a href="https://www.nature.com/articles/s41375-026-02885-7">doi:10.1038/s41375-026-02885-7</a></p>Risk stratification of patients with <i>TP53</i>-mutated myeloproliferative neoplasms Leukemia Journal February 26, 2026 Original source
Prof. Peter Duesberg—Molecular Biologist <i>par excellence</i>. 2 December, 1936–13 January, 2026 <p>Leukemia, Published online: 25 February 2026; <a href="https://www.nature.com/articles/s41375-026-02891-9">doi:10.1038/s41375-026-02891-9</a></p>Prof. Peter Duesberg—Molecular Biologist <i>par excellence</i>. 2 December, 1936–13 January, 2026 Leukemia Journal February 26, 2026 Original source
Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia <p>Leukemia, Published online: 25 February 2026; <a href="https://www.nature.com/articles/s41375-026-02897-3">doi:10.1038/s41375-026-02897-3</a></p>Correction: Peripheral blood flow cytometry-based definition of plasma cell leukemia Leukemia Journal February 26, 2026 Original source
Robot-assisted MRI/US transperineal target prostate biopsy with Biobot Mona Lisa 2.0: first experience in Europe <p>Prostate Cancer and Prostatic Diseases, Published online: 25 February 2026; <a href="https://www.nature.com/articles/s41391-026-01094-8">doi:10.1038/s41391-026-01094-8</a></p>Robot-assisted MRI/US transperineal target prostate biopsy with Biobot Mona Lisa 2.0: first experience in Europe Prostate Cancer Journal February 26, 2026 Original source
PSMA-PET imaging in prostate cancer patients with high-risk biochemical recurrence: implications from an “EMBARK-Like” cohort <p>Prostate Cancer and Prostatic Diseases, Published online: 25 February 2026; <a href="https://www.nature.com/articles/s41391-026-01096-6">doi:10.1038/s41391-026-01096-6</a></p>PSMA-PET imaging in prostate cancer patients with high-risk biochemical recurrence: implications from an “EMBARK-Like” cohort Prostate Cancer Journal February 26, 2026 Original source
Commentary on "Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer" <p>Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by limited treatment options and poor prognosis. Immune checkpoint blockade, particularly via programmed cell death protein-1/programmed death-ligand 1 inhibition, has improved outcomes in selected patients with TNBC; however, resistance remains a major barrier. Recent studies have identified B7-H3 (CD276) as a key immune-suppressive molecule overexpressed in TNBC, correlating with… Journal for ImmunoTherapy of Cancer February 25, 2026 Original source
What’s the Difference Between Outpatient Stem Cell Transplants and Inpatient Transplants? <p>A stem cell transplant is a procedure during which doctors either replace diseased or ineffective stem cells with healthy new stem cells as treatment for leukemia, lymphoma, and other blood cancers or diseases. The infusion of healthy stem cells reestablishes a healthy blood supply and rebuilds the body’s immune system to effectively fight cancer. At Dana-Farber, patients can be eligible for a stem cell… Dana-Farber Cancer Institute February 25, 2026 Original source
Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment <p>Tumor-associated macrophages are key myeloid cells in the tumor microenvironment (TME), acting as essential orchestrators of innate and adaptive immune responses. The efficacy of current antitumoral treatments can be promoted by macrophages, thanks to their phagocytosis, tumoricidal activity, and eliciting of adaptive immunity; or restricted by their expression of inhibitory counter-receptors (such as programmed death-ligand 1 or signal regulatory protein… Journal for ImmunoTherapy of Cancer February 24, 2026 Original source
Commentary on "Comparative efficacy and safety of PSCA CAR-engineered V{delta}1 {gamma}{delta} T cells for immunotherapy of pancreatic cancer" <p>Adoptive transfer of unmodified T cells has shown limited clinical benefit, prompting a shift toward chimeric antigen receptor (CAR) engineering to enhance activation, persistence, and tumor specificity. CAR technology positions T cells as promising carriers due to their innate-like cytotoxicity and HLA-independent recognition. Evidence from αβ CAR T-cell trials indicates that CAR T cells can persist for months to years… Journal for ImmunoTherapy of Cancer February 24, 2026 Original source
HOXD13-mediated immune crosstalk between cancer cells and tumor-associated macrophages drives colorectal cancer progression Background <p>The complex tumor microenvironment (TME) of colorectal cancer (CRC), composed of diverse cellular components and dynamic interactions, constitutes a major barrier to effective immunotherapy and facilitates disease progression. There is a pressing need to elucidate CRC-intrinsic factors that induce the immunosuppressive TME. Here, we explored the role of homeobox D13 (HOXD13) in shaping the immune microenvironment of CRC and… Journal for ImmunoTherapy of Cancer February 24, 2026 Original source
The path forward for T cell engagers in patients with prostate cancer Abstract <p>T cell engagers (TCEs) recruit T cells to the tumor microenvironment (TME) to induce antitumor immune responses. TCEs have demonstrated promising clinical responses in patients with metastatic castration-resistant prostate cancer and have advanced into phase 3 clinical trials. Here we provide an overview of the mechanisms of action of TCEs, including both CD3-targeted and CD28-targeted agents, and review the… Journal for ImmunoTherapy of Cancer February 24, 2026 Original source
Effective allogeneic natural killer cell therapy for pancreatic adenocarcinoma avails conserved activating receptors and evades HLA I-driven inhibition Background <p>At diagnosis, ~80% of pancreatic ductal adenocarcinomas (PDAC) have metastasized. Relapse is thus common even among patients who undergo surgical resection, the only curative option. PDAC progresses rapidly, and existing immunotherapies have been ineffective. We hypothesized that natural killer (NK) cell immunotherapies could be effective against PDAC because they recognize conserved and heterogeneous features associated with cellular stress and… Journal for ImmunoTherapy of Cancer February 24, 2026 Original source
Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer Background <p>Most colorectal cancers (CRCs) are mismatch repair-proficient (pMMR) and microsatellite stable (MSS), and they respond poorly to immune checkpoint inhibitors (ICIs). Radiotherapy (RT) can promote antitumor immunity but may also trigger adaptive immune suppression through checkpoint upregulation, providing a rationale for combination therapies.</p> Methods <p>We integrated transcriptomic analyses from The Cancer Genome Atlas and Gene Expression Omnibus cohorts—annotated for… Journal for ImmunoTherapy of Cancer February 24, 2026 Original source
Macrophage Mtdh deficiency discordantly regulated tumor growth and metastasis through increased thrombospondin-1 production Objective <p>Metadherin (MTDH) is a recognized oncogene involved in the progression and metastasis of various cancers. However, further studies are needed to elucidate the biological role of MTDH, which is expressed in macrophages during tumor progression.</p> Methods <p>Mouse colorectal cancer and melanoma cells were subcutaneously and intravenously injected into myeloid-specific <i>Mtdh</i> knockout mice to evaluate tumor growth and lung metastases.… Journal for ImmunoTherapy of Cancer February 24, 2026 Original source
Specific depletion of TIGIThigh CD226- clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting Background <p>Global clinical programs based on TIGIT (T cell immunoglobulin and ITIM domain) blockade have been terminated due to inadequate clinical efficacy. New approaches are needed to increase the antitumor activity of anti-TIGIT-based immunotherapy.</p> Methods <p>Multiomics analyses, including single-cell RNA sequencing (scRNA-seq), single-cell TCR sequencing (scTCR-seq), and The Cancer Genome Atlas bulk RNA-seq, were performed to profile TIGIT and the… Journal for ImmunoTherapy of Cancer February 24, 2026 Original source
Serotonin transporter SERT: a novel immune checkpoint for CD8+ T cell antitumor therapy <p>This Highlight describes a key observation where serotonin transporter (SERT) was shown to suppress CD8<sup>+</sup> T cell antitumor responses via depletion of intratumoral 5-HT. While selective serotonin reuptake inhibitors (SSRIs)—among the most widely used antidepressants—significantly inhibit tumor growth and enhance T cell-mediated antitumor immunity in both mouse models and human xenografts, showing remarkable synergy with anti-PD-1 therapy. These findings emphasize… Journal for ImmunoTherapy of Cancer February 24, 2026 Original source
Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany <p>Prostate Cancer and Prostatic Diseases, Published online: 24 February 2026; <a href="https://www.nature.com/articles/s41391-026-01092-w">doi:10.1038/s41391-026-01092-w</a></p>Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany Prostate Cancer Journal February 24, 2026 Original source
Can Castor Oil Cure Cancer? <p>Castor oil is a thick, yellowish vegetable oil extracted from castor beans native to warm temperate regions. It is often available in grocery stores, pharmacies, and convenience stores.  Despite its long history in providing laxative results, there’s little research to suggest this product can be used as a remedy for other health concerns such as cancer.  Can castor oil be used to cure cancer or reduce my risk of it?   Castor oil has many potential uses and applications, ... <a class="read-more" href="https://blog.dana-farber.org/insight/2026/02/can-castor-oil-cure-cancer/" title="Can… Dana-Farber Cancer Institute February 24, 2026 Original source
Missing the full picture: Pathology, anatomy, and operator effects in HoLEP comparisons <p>Prostate Cancer and Prostatic Diseases, Published online: 24 February 2026; <a href="https://www.nature.com/articles/s41391-026-01093-9">doi:10.1038/s41391-026-01093-9</a></p>Missing the full picture: Pathology, anatomy, and operator effects in HoLEP comparisons Prostate Cancer Journal February 24, 2026 Original source